Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
申请人:——
公开号:US20040082641A1
公开(公告)日:2004-04-29
The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
本发明提供了治疗和预防早期心脏和早期心血管疾病的方法,例如缺血性疾病,如左心室肥大,冠状动脉疾病,高血压,急性高血压紧急情况,心肌病,心力衰竭,运动耐受性,慢性心力衰竭,心律失常,心脏心律失常,晕厥,动脉硬化,轻度慢性心力衰竭,心绞痛,心脏旁路再闭塞,间歇性跛行(闭塞性动脉硬化),舒张功能和收缩功能障碍,以及通过给予糖原磷酸化酶抑制剂化合物来提高心脏移植的成功率。